GLB-001

DRUG2 trials

Sponsors

GluBio Therapeutics Inc., Hangzhou GluBio Pharmaceutical Co., Ltd.

Conditions

Acute Myeloid LeukemiaEssential ThrombocythemiaMyelodysplastic SyndromesMyelofibrosisMyeloid MalignancyPolycythemia Vera

Phase 1

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

RecruitingNCT06146257

GluBio Therapeutics Inc.Acute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2024-01-11End: 2026-10-08Target: 48Updated: 2026-04-13

A Study of GLB-001 in Patients With Myeloid Malignancies

RecruitingNCT06378437

Hangzhou GluBio Pharmaceutical Co., Ltd.Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndromes +3

Start: 2024-05-24End: 2027-12-31Target: 108Updated: 2025-08-19